Dermatology · Auburn, AL
NPI
1326201856
Since 2008
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
1935 E Glenn Ave
Auburn, AL, 36830
Phone (334) 539-8049
Groups this clinician bills Medicare through
Medicare paid, 2024
$494K
5,505 services
Medicare patients, 2024
1,056
Average age 76
Drug cost, 2024
$2.5M
2,203 prescriptions
Company payments, 2025
$42K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Kevin T Nash was code 17003 (destruction skin lesion), 1,848 times for 312 patients. In total Kevin T Nash billed 5,505 services in 72 codes, and Medicare paid $494K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-06-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 1,848 | 312 | $4.01 | $7,417 |
| 99213 Office E&M - Established | Office | 810 | 616 | $51.74 | $42K |
| 17000 Destruction Skin Lesion | Office | 473 | 391 | $31.23 | $15K |
| 17311 Mohs Surgery | Office | 354 | 259 | $397.51 | $141K |
| 11102 Skin Biopsy | Office | 352 | 300 | $58.75 | $21K |
| 13121 Wound Repair - All Levels | Office | 194 | 163 | $220.42 | $43K |
| 99214 Office E&M - Established | Office | 179 | 139 | $70.47 | $13K |
| 13132 Wound Repair - All Levels | Office | 166 | 149 | $168.23 | $28K |
| 11103 Skin Biopsy | Office | 125 | 69 | $32.39 | $4,048 |
| 11602 Skin Lesion Excision | Office | 115 | 100 | $83.65 | $9,620 |
| 99203 Office E&M - New | Office | 109 | 109 | $59.22 | $6,455 |
| 17110 Destruction Skin Lesion | Office | 95 | 91 | $65.03 | $6,178 |
| 17313 Mohs Surgery | Office | 89 | 68 | $384.42 | $34K |
| 17312 Mohs Surgery | Office | 70 | 57 | $285.68 | $20K |
| 17004 Destruction Skin Lesion | Office | 66 | 57 | $99.77 | $6,585 |
By year: 2022 $525K for 5,741 services; 2023 $645K for 5,854 services; 2024 $494K for 5,505 services.
Medicare prescription drug claims, 2024
In 2024, the drug Kevin T Nash prescribed most often to Medicare patients was Clobetasol Propionate, with 351 prescriptions and refills. In total Kevin T Nash wrote 2,203 Medicare prescriptions that cost $2.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Clobetasol Propionate Generic | 351 | 356 | 193 | $15K |
| Doxycycline Hyclate Generic | 174 | 189 | 130 | $2,401 |
| Desonide Generic | 157 | 162 | 92 | $12K |
| Mupirocin Generic | 146 | 146 | 98 | $1,104 |
| Triamcinolone Acetonide Generic | 110 | 118 | 65 | $1,936 |
| Hydrocortisone Generic | 106 | 107 | 63 | $871 |
| Gabapentin Generic | 97 | 115 | 32 | $1,191 |
| Clindamycin Phosphate Generic | 95 | 105 | 37 | $4,881 |
| Ketoconazole Generic | 76 | 77 | 26 | $2,538 |
| Humira(Cf) Pen Adalimumab | 72 | 72 | Under 11 | $854K |
| Minoxidil Generic | 63 | 121 | 18 | $404 |
| Metronidazole Generic | 62 | 63 | 28 | $3,693 |
| Fluorouracil Generic | 58 | 62 | 49 | $3,859 |
| Imiquimod Generic | 52 | 60 | 37 | $2,130 |
| Dupixent Syringe Dupilumab | 46 | 46 | Under 11 | $171K |
Brand drugs: 316 claims; generic drugs: 1,887 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Kevin T Nash $42K ($42K in general payments such as food, travel and fees) from 16 companies. The largest payer was Janssen Biotech, Inc. with $41K.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 29 | $41K |
| Abbvie Inc. ABBV | 49 | $527 |
| Amgen Inc. AMGN | 9 | $204 |
| Organon LLC OGN | 5 | $176 |
| Regeneron Healthcare Solutions, Inc. REGN | 8 | $165 |
| Arcutis Biotherapeutics, Inc. ARQT | 3 | $159 |
| Sun Pharmaceutical Industries Inc. SUNPHARMA.NS | 1 | $107 |
| Mayne Pharma Commercial LLC | 9 | $87.18 |
| Pfizer Inc. PFE | 5 | $85.32 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $65.01 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.